DK0690675T5 - Nukleinsyre, der koder for en tumorafstödningsantigenprecursor - Google Patents

Nukleinsyre, der koder for en tumorafstödningsantigenprecursor

Info

Publication number
DK0690675T5
DK0690675T5 DK94911498T DK94911498T DK0690675T5 DK 0690675 T5 DK0690675 T5 DK 0690675T5 DK 94911498 T DK94911498 T DK 94911498T DK 94911498 T DK94911498 T DK 94911498T DK 0690675 T5 DK0690675 T5 DK 0690675T5
Authority
DK
Denmark
Prior art keywords
tumor rejection
rejection antigen
nucleic acid
antigen precursor
acid encoding
Prior art date
Application number
DK94911498T
Other languages
English (en)
Other versions
DK0690675T3 (da
Inventor
Vincent Brichard
Pel Aline Van
Thomas Wolfel
Thierry Boon-Falleur
Plaen Etienne De
Catia Traversari
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK0690675T3 publication Critical patent/DK0690675T3/da
Publication of DK0690675T5 publication Critical patent/DK0690675T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94911498T 1993-03-18 1994-03-09 Nukleinsyre, der koder for en tumorafstödningsantigenprecursor DK0690675T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/032,978 US5620886A (en) 1993-03-18 1993-03-18 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1994/002487 WO1994021126A1 (en) 1993-03-18 1994-03-09 Nucleic acid coding for a tumor rejection antigen precursor

Publications (2)

Publication Number Publication Date
DK0690675T3 DK0690675T3 (da) 2004-06-01
DK0690675T5 true DK0690675T5 (da) 2008-11-17

Family

ID=21867896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94911498T DK0690675T5 (da) 1993-03-18 1994-03-09 Nukleinsyre, der koder for en tumorafstödningsantigenprecursor

Country Status (17)

Country Link
US (2) US5620886A (da)
EP (1) EP0690675B1 (da)
JP (1) JP3433322B2 (da)
CN (1) CN1072719C (da)
AT (1) ATE258379T1 (da)
AU (1) AU675707B2 (da)
CA (1) CA2158446C (da)
DE (2) DE69433518T4 (da)
DK (1) DK0690675T5 (da)
ES (1) ES2210252T3 (da)
FI (1) FI954360A (da)
NO (1) NO953601L (da)
NZ (1) NZ263348A (da)
PT (1) PT690675E (da)
TW (1) TW442568B (da)
WO (1) WO1994021126A1 (da)
ZA (1) ZA941812B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
CA2188432C (en) * 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
JP2001503966A (ja) * 1996-06-25 2001-03-27 ザ ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 脳グリコーゲンホスホリラーゼ癌抗原
PT970206E (pt) 1997-01-27 2008-10-28 Ludwig Inst Cancer Res Ácidos nucleicos lage-1 associados a tumores
US5879892A (en) 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
WO1999037797A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Antigen-specific cells, methods of generating these cells and uses thereof
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Mage-a12 항원성 펩티드 및 그의 용도
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
CA2571168A1 (en) 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP1787124A2 (en) 2004-06-23 2007-05-23 The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
US20060159694A1 (en) * 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
EP2371851A3 (en) * 2005-06-17 2012-08-01 Mannkind Corporation Epitope analogues
MX2007015950A (es) 2005-06-17 2008-04-04 Mannkind Corp Inmunoterapeuticos multivalentes de transporte y ampliacion para carcinoma.
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
SG184310A1 (en) 2010-04-13 2012-10-30 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
EP3998079A1 (en) 2014-06-06 2022-05-18 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
BR112017025191A2 (pt) 2015-05-29 2018-07-31 Bristol-Myers Squibb Company anticorpos contra ox40 e uso dos mesmos
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Also Published As

Publication number Publication date
AU6399394A (en) 1994-10-11
JPH08507693A (ja) 1996-08-20
EP0690675B1 (en) 2004-01-28
FI954360A0 (fi) 1995-09-15
CA2158446A1 (en) 1994-09-29
CA2158446C (en) 2009-01-06
EP0690675A4 (en) 1998-12-23
US5854203A (en) 1998-12-29
DE69433518D1 (de) 2004-03-04
FI954360A (fi) 1995-09-15
CN1093406A (zh) 1994-10-12
JP3433322B2 (ja) 2003-08-04
ZA941812B (en) 1994-10-13
ES2210252T3 (es) 2004-07-01
PT690675E (pt) 2004-06-30
NZ263348A (en) 1996-06-25
DE69433518T2 (de) 2004-06-24
CN1072719C (zh) 2001-10-10
ATE258379T1 (de) 2004-02-15
US5620886A (en) 1997-04-15
EP0690675A1 (en) 1996-01-10
DE69433518T4 (de) 2009-07-23
WO1994021126A1 (en) 1994-09-29
DK0690675T3 (da) 2004-06-01
AU675707B2 (en) 1997-02-13
NO953601D0 (no) 1995-09-13
TW442568B (en) 2001-06-23
NO953601L (no) 1995-10-31

Similar Documents

Publication Publication Date Title
DK0690675T5 (da) Nukleinsyre, der koder for en tumorafstödningsantigenprecursor
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
NO955063D0 (no) Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav
NO960158D0 (no) Fremgangsmåte til diagnostisering av en lidelse ved å bestemme ekspresjon av GAGE-tumor-rejeksjonsantigenforlöpere
ES2167561T3 (es) Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.
HUP9801608A2 (hu) A 11. típusú humán papillomavírusból származó L1-fehérjét kódoló szintetikus HPV6/11-L1-hibrid-DNS
DE69008326D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
DE69010171D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
ES2192602T3 (es) Molecula de acido nucleico aislada y truncada, que codifica el antigeno de rechazo tumurall gage.
DE69022491T3 (de) Herstellung von Tertiär-Kohlenwasserstoff-Silyl-Verbindungen.
FR2575466B1 (fr) Nouveaux complexes de silicium hexacoordines, leur procede de preparation et leur application
DE3767493D1 (de) Wanderschichtreaktor zur entfernung von unerwuenschten, gasfoermigen bestandteilen aus gasen.
DE60218678D1 (de) Verfahren zur herstellung von 2,4-didesoxyhexosen und 2,4,6-tridesoxyhexosen
DE69008382D1 (de) Verfahren zur Herstellung von Organosiliziumverbindungen.
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE3780665D1 (de) Mehrstufiges reduktionsverfahren zur herstellung von ferromagnetischem chromdioxid.
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
IT1180220B (it) Miscela di composti diastereoisomeri, ottenuti da (-)-5-(1-idrossi-1-metiletil)-2-metil-2-cicloesen-1-one, avente attivita' mucosecretolitica, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono
ATE15486T1 (de) Verfahren zur herstelling von threo-3-(3,4dihydroxyphenyl)serin.
IT8025322A0 (it) Procedimento per la realizzazione di calzature, nonche' calzatura realizzata.
ATE55257T1 (de) Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen.
IT8620610A0 (it) Procedimento per la fabbricazione di laterizi contenenti fanghi conciari.